



Advancing Therapeutics.
Improving Lives.

Gilead Sciences, Inc.

Medical Affairs

Call for Proposals for CHIME program (Conquering Hepatitis via Micro-Elimination)

Gilead supports the efforts of governments and partners with professional organizations, patient advocacy groups, payers and healthcare professionals who have declared their intention and commitment to work toward the WHO goal of eliminating viral hepatitis around the world by 2030.

Some of the defining features of the WHO goal are:

- 90% reduction in new HCV cases (e.g., screening of blood donations and risk reduction)
- 90% diagnosis of those infected with HCV
- 80% of eligible people with HCV treated
- 65% reduction in death

Micro-elimination focuses on breaking down national and international elimination goals into smaller goals which are relevant for defined populations.

Micro-elimination efforts require stakeholders to set pragmatic goals, while the people who are best informed about the HCV epidemic in a sub-population can tailor research to address local circumstances where data is needed.

In an effort to support micro-elimination efforts, the Gilead Medical Affairs team will support individual projects of no more than \$350,000 USD or equivalent sum. It is Gilead's intent to support up to 30 well-defined projects.

Successful projects should demonstrate clear objectives, defined timelines, a comprehensive operational plan, and proposed data which has relevance to the medical community and policy makers. Investigators should consider a presentation of findings to policy makers, with an aim of providing relevant evidence to support governmental or organizational public health objectives with respect to HCV elimination, where applicable, consistent with WHO goals.


Gilead retains the right to accept or deny any proposal and will attempt to ensure submissions fulfill a data need, and represent geographic distribution across the world.

Gilead will not consider requests solely for HCV screening costs (including test kits) or proposals which include HCV study drug. Proposals should be agnostic to a specific HCV drug.

Gilead will consider support for research proposals that do the following:

- Focus on a defined population such as but not limited to:
 - Specific demographic
 - Defined geographical area such as neighborhood, city, state, or region
 - Discrete population within a health care network or system
- Focus on a data gap for the defined population. Examples include:
 - Surveillance data pertaining to the cascade of care in geographies or populations which currently have inadequate data or strategic information systems for monitoring HCV infection

- Preventative strategies pertaining to: unsafe blood transfusion, health care injections, or harm reduction strategies
- Understanding or intervening on a 'leakage in the cascade'
- Consider presenting data to policy makers
- Definitively address one or more of the following areas (A-G) of the cascade of care:



A. Surveillance B. Preventative C. Testing strategy D. Linkage to treater E. Complete Treatment F. Achieve Cure G. Re-infection

Letter of intent should adhere to the following:

- Sponsoring institution has not already received a grant from a Gilead Medical Affairs Program (i.e., CITE, SCALE, or NoCo) or is currently receiving support from FOCUS
- Proposed budget is ≤ \$350,000 USD equivalents
 - Including overhead costs and applicable taxes
- Proposed overhead costs are ≤ 30% of the total budget
- The proposed study design will not take longer than 24 months to complete
- Funding for sole purpose of screening costs is not acceptable for CHIME
- Funding for or contribution of HCV study drug is not acceptable for CHIME
- No more than one subsite that will require contract negotiations and/or Institutional Review Board (IRB) or Ethics Committee (EC) review, or other barriers that will lead to delays in study start-up

Key Dates & Program Specifics:

- Gilead will evaluate and award submissions on a rolling basis during monthly reviews.
- Letter of Intent (LOI) – should be entered into the provided template. Proposals should not exceed 1,000 word limit
 - **30 April 2018:** LOI submission window opens
 - **31 August 2018:** LOI submission window closes

LOI applicants should use the downloadable **LOI Form** available at

<http://www.gilead.com/research/conquering-hepatitis-via-micro-elimination>

LOI forms and Overhead Policy forms should be submitted to: Chime@gilead.com.



Advancing Therapeutics.
Improving Lives.

- Full application submission

A review of the LOIs will result in invitations for selected LOI applicants to submit a full application.

Full application submissions should be made by clicking on Apply Online at <http://www.gilead.com/research/investigator-sponsored>

Gilead plans to approve awards for these research proposals, dependent upon availability of funds and receipt of meritorious applications. Gilead anticipates that approximately 30 awards will be granted. No individual study may exceed \$350,000 USD equivalents. Awards shall be for research purposes only.

Questions about the announcement or application process should be submitted to your local Gilead Medical Scientist or Chime@gilead.com. Gilead reserves the right to approve or decline any application. Applications are reviewed by an internal review committee. Award of a grant in any one cycle does not infer that a subsequent grant will be awarded without further application and approval.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

1. Lazarus et al, J Hepatology 2017 vol. 67, 665-666
2. WHO. Global Hepatitis Report 2017 Available at: <http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/> (accessed April 2018)